HBV整合的分子模式及其对肝细胞癌发生和预后的影响

摘要/Abstract

摘要： 肝细胞癌(HCC)是全球高发恶性肿瘤,慢性乙型肝炎病毒(HBV)感染是其最主要的致病诱因,全球约50%的HCC病例由慢性HBV感染所致。在HBV相关HCC的发病进程中,双重机制发挥关键作用:一是HBV持续感染引发的长期慢性肝脏炎症,为肝细胞恶性转化提供适宜的微环境;二是HBV DNA整合入宿主基因组形成整合DNA(iDNA),iDNA可通过多种途径驱动癌变。在基因层面,iDNA高频整合于TERT启动子、KMT2B等癌症相关基因区域,通过干扰基因正常表达调控,直接导致抑癌基因功能失活或原癌基因异常激活;在染色体层面,iDNA的插入可诱发宿主染色体易位,破坏基因组稳定性,加速细胞的恶性转化过程。本综述系统梳理了不同HCC队列研究中iDNA的分子特征与分布模式,深入分析其对HCC发生、发展及患者预后的影响,旨在为全面解析iDNA介导的HBV相关HCC致癌机制提供新的研究思路与理论视角。

关键词: 乙型肝炎病毒, 整合, 肝细胞癌, 克隆扩增

施烨娟, 陈香梅. HBV整合的分子模式及其对肝细胞癌发生和预后的影响[J]. 肝脏, 2025, 30(9): 1171-1174.

/ 推荐

参考文献

[1] Villanueva A. Hepatocellular carcinoma [J]. N Engl J Med, 2019, 380(15): 1450-1462.
[2] Llovet J M, Kelley R K, Villanueva A, et al. Hepatocellular carcinoma [J]. Nat Rev Dis Primers, 2021, 7(1): 6.
[3] Cheung T T, Yu S C, Chan S L, et al. The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021 [J]. Hepatobiliary Surg Nutr, 2023, 12(3): 366-385.
[4] Zhao K, Liu A, Xia Y. Insights into hepatitis B virus DNA integration-55 years after virus discovery [J]. Innovation (Camb), 2020, 1(2): 100034.
[5] Ho D W, Lo R C, Chan L K, et al. Molecular pathogenesis of hepatocellular carcinoma [J]. Liver Cancer, 2016, 5(4): 290-302.
[6] Li X, Zhang J, Yang Z, et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma [J]. J Hepatol, 2014, 60(5): 975-984.
[7] Jang J W, Kim H S, Kim J S, et al. Distinct patterns of HBV integration and TERT alterations between in tumor and non-tumor tissue in patients with hepatocellular carcinoma [J]. Int J Mol Sci, 2021, 22(13).
[8] Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma [J]. Gut, 2022, 71(3): 616-626.
[9] Lyu X, Sze K M, Lee J M, et al. Disparity landscapes of viral-induced structural variations in HCC: mechanistic characterization and functional implications [J]. Hepatology, 2025, 81(6): 1805-1821.
[10] Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance [J]. World J Gastroenterol, 2014, 20(18): 5427-5434.
[11] Chen Y, Yu D, Zhang W, et al. HBV subgenotype C2 infection, A1762T/G1764A mutations may contribute to hepatocellular carcinoma with cirrhosis in southeast China [J]. Iran J Public Health, 2012, 41(11): 10-18.
[12] Malmström S, Eilard A, Larsson S B, et al. Genotype impact on long-term virological outcome of chronic hepatitis B virus infection [J]. J Clin Virol, 2012, 54(4): 321-326.
[13] Wong G L, Chan H L, Yiu K K, et al. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma [J]. Aliment Pharmacol Ther, 2013, 37(5): 517-526.
[14] Datta S, Roychoudhury S, Ghosh A, et al. Distinct distribution pattern of hepatitis B virus genotype C and D in liver tissue and serum of dual genotype infected liver cirrhosis and hepatocellular carcinoma patients [J]. PLoS One, 2014, 9(7): e102573.
[15] Raza S A, Clifford G M, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review [J]. Br J Cancer, 2007, 96(7): 1127-1134.
[16] Álvarez E G, Demeulemeester J, Otero P, et al. Aberrant integration of hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture [J]. Nat Commun, 2021, 12(1): 6910.
[17] Barra V, Fachinetti D. The dark side of centromeres: types, causes and consequences of structural abnormalities implicating centromeric DNA [J]. Nat Commun, 2018, 9(1): 4340.
[18] Sung W K, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma [J]. Nat Genet, 2012, 44(7): 765-769.
[19] Zhao L H, Liu X, Yan H X, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma [J]. Nat Commun, 2016, 7: 12992.
[20] Saigo K, Yoshida K, Ikeda R, et al. Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma [J]. Hum Mutat, 2008, 29(5): 703-708.
[21] Nault J C, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions [J]. Nat Commun, 2013, 4: 2218.
[22] Sze K M, Ho D W, Chiu Y T, et al. Hepatitis B virus-telomerase reverse transcriptase promoter integration harnesses host ELF4, resulting in telomerase reverse transcriptase gene transcription in hepatocellular carcinoma [J]. Hepatology, 2021, 73(1): 23-40.
[23] Ferber M J, Montoya D P, Yu C, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers [J]. Oncogene, 2003, 22(24): 3813-3820.
[24] Paterlini-Bréchot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene [J]. Oncogene, 2003, 22(25): 3911-3916.
[25] Wang H, Zhang J, Li H, et al. FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers [J]. Front Oncol, 2022, 12: 918719.
[26] Que Z, Xi Z, Qi D, et al. Src/FN1 pathway activation drives tumor cell cluster formation and metastasis in lung cancer: a promising therapeutic target [J]. Sci Adv, 2025, 11(28): eadv7377.
[27] Li C L, Ho M C, Lin Y Y, et al. Cell-free virus-host chimera DNA from hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer [J]. Hepatology, 2020, 72(6): 2063-2076.
[28] Yeh S H, Li C L, Lin Y Y, et al. Hepatitis B virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC [J]. Cell Mol Gastroenterol Hepatol, 2023, 15(4): 921-929.
[29] Zhang X, Liu S, Shen C, et al. DNA methylation consistency implicates the primary tumor cell origin of recurrent hepatocellular carcinoma [J]. Epigenomics, 2015, 7(4): 581-592.
[30] Zheng B, Liu X L, Fan R, et al. The landscape of cell-free HBV integrations and mutations in cirrhosis and hepatocellular carcinoma patients [J]. Clin Cancer Res, 2021, 27(13): 3772-3783.